Literature DB >> 27034386

Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome.

M S Camus1, H L Priest2, J W Koehler3, E A Driskell4, P M Rakich5, M R Ilha6, P M Krimer5.   

Abstract

A 2-tiered histologic grading scheme for canine cutaneous mast cell tumors (MCTs) is based on morphologic characteristics of neoplastic cells, including karyomegaly, multinucleation, nuclear pleomorphism, and mitotic figures. Aspirates from MCTs may provide the same information more quickly, inexpensively, and less invasively. This study used these criteria to develop a cytologic grading scheme for canine MCTs to predict outcome. Three anatomic pathologists graded histologic samples from 152 canine MCTs. Three clinical pathologists evaluated aspirates from these masses using similar criteria. A cytologic grading scheme was created based on correlation with histologic grade and evaluated with a kappa statistic. Survival was evaluated with Kaplan-Meier survival curves. Cox proportional hazards regression was used to estimate hazard ratios for tumor grades and individual grading components. Simple logistic regression tested for relationships between risk factors and mortality. The cytologic grading scheme that best correlated with histology (kappa = 0.725 ± 0.085) classified a tumor as high grade if it was poorly granulated or had at least 2 of 4 findings: mitotic figures, binucleated or multinucleated cells, nuclear pleomorphism, or >50% anisokaryosis. The cytologic grading scheme had 88% sensitivity and 94% specificity relative to histologic grading. Dogs with histologic and cytologic high grade MCTs were 39 times and 25 times more likely to die within the 2-year follow-up period, respectively, than dogs with low grade MCTs. High tumor grade was associated with increased probability of additional tumors or tumor regrowth. This study concluded that cytologic grade is a useful predictor for treatment planning and prognostication.
© The Author(s) 2016.

Entities:  

Keywords:  cytology; dog; grading; histology; mast cell tumor; neoplasia; skin

Mesh:

Year:  2016        PMID: 27034386     DOI: 10.1177/0300985816638721

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  9 in total

1.  Τhe Effect of Opioid Administration on Cytologic and Histopathologic Diagnosis of Canine Cutaneous Mast Cell Tumors Treated by Surgical Excision.

Authors:  Christina Marouda; Tilemahos Anagnostou; Ioannis Savvas; Lysimachos G Papazoglou; Dimitra Psalla
Journal:  Vet Sci       Date:  2022-04-22

2.  Veterinary Pathology - A Path Forward with New Directions and Opportunities.

Authors:  Tracy Stokol
Journal:  Front Vet Sci       Date:  2016-08-31

Review 3.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

4.  Tolerability and Effects of 2-Aminoethyl Dihydrogen Phosphate in Dogs With Mast Cell Tumors.

Authors:  Eric Vieira Januário; Samanta Rios Melo; Durvanei Augusto Maria; Carla Aparecida Batista Lorigados; Aline Magalhães Ambrósio; Marcia Mery Kogika; Bruno Cogliati; Helio Junji Shimozako; Julia Maria Matera
Journal:  Front Vet Sci       Date:  2022-07-12

5.  Sentinel Lymph Node Mapping with Indirect Lymphangiography for Canine Mast Cell Tumour.

Authors:  Andrea De Bonis; Francesco Collivignarelli; Andrea Paolini; Ilaria Falerno; Valentina Rinaldi; Roberto Tamburro; Amanda Bianchi; Rossella Terragni; Jacopo Gianfelici; Paolo Frescura; Giulia Dolce; Eleonora Pagni; Roberta Bucci; Massimo Vignoli
Journal:  Vet Sci       Date:  2022-09-08

6.  Association between case signalment and disease diagnosis in urinary bladder disease in Australian cats and dogs.

Authors:  Emily Jones; John Alawneh; Mary Thompson; Rachel Allavena
Journal:  J Vet Diagn Invest       Date:  2021-04-02       Impact factor: 1.279

7.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

Review 8.  Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.

Authors:  Michael Willmann; Vilma Yuzbasiyan-Gurkan; Laura Marconato; Mauro Dacasto; Emir Hadzijusufovic; Olivier Hermine; Irina Sadovnik; Susanne Gamperl; Mathias Schneeweiss-Gleixner; Karoline V Gleixner; Thomas Böhm; Barbara Peter; Gregor Eisenwort; Richard Moriggl; Zhixiong Li; Mohamad Jawhar; Karl Sotlar; Erika Jensen-Jarolim; Veronika Sexl; Hans-Peter Horny; Stephen J Galli; Michel Arock; David M Vail; Matti Kiupel; Peter Valent
Journal:  Front Vet Sci       Date:  2021-12-10

9.  Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).

Authors:  Thomas R De Ridder; Justine E Campbell; Cheryl Burke-Schwarz; David Clegg; Emily L Elliot; Samuel Geller; Wendy Kozak; Stephen T Pittenger; Jennifer B Pruitt; Jocelyn Riehl; Julie White; Melissa L Wiest; Chad M Johannes; John Morton; Pamela D Jones; Peter F Schmidt; Victoria Gordon; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-06-16       Impact factor: 3.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.